2025-04-14T23:01:51-04:00 2024-09-30 461041593 FINANCIAL SOLUTION ADVISORS PLLC 4350 PABLO PROFESSIONAL CT STE 200 JACKSONVILLE FL 322243224 990 2023-10-01 453710305 IDAHO VETERANS RESEARCH & EDUCATION FOUNDATION IDAH 2084221000 500 W FORT STREET BLDG 117 BOISE ID 83702 MARGARET K ALDAPE EXECUTIVE DIRECTOR 2084221000 2025-04-07 true MICHAEL B MCLEOD CPA P00966646 9042962024 2025-04-14 2023 2025-03-06 01:10:19Z MARGARET K ALDAPE 500 W FORT STREET BLDG 117 BOISE ID 83702 1118208 false X WWW.IVREF.ORG X 2011 ID TO ADVANCE THE RESEARCH AND EDUCATION MISSION OF THE DEPARTMENT OF VETERANS AFFAIRS AND SPECIFICALLY THE BOISE VA MEDICAL CENTER THROUGH THE SUPPORT OF RESEARCH AND EDUCATION RELATED ACTIVITIES. 7 7 18 7 0 708008 480899 617920 9721 17281 101 2108 717830 1118208 0 0 691574 689757 0 0 216500 442774 908074 1132531 -190244 -14323 653845 661046 31174 51986 622671 609060 X TO ADVANCE THE RESEARCH AND EDUCATION MISSION OF THE DEPARTMENT OF VETERANS AFFAIRS AND SPECIFICALLY THE BOISE VA MEDICAL CENTER THROUGH THE SUPPORT OF RESEARCH AND EDUCATION RELATED ACTIVITIES. false false 893258 617920 EXPENDITURES RELATED TO RESEARCH AND EDUCATION. RESEARCH EXPENSES ASSOCIATED WITH THE FOLLOWING MAJOR GRANT PROJECTS: 1)NIH (U OF IDAHO SUB-AWARD) - IDAHO INBRE PROGRAM IVREF DOUCETTE 2)NIH (U OF IDAHO SUB-AWARD) - DHHS NIH INBRE4 IVREF HOBDEY DRP 3)NIH (U OF IDAHO SUB-AWARD) - DHHS NIH INBRE4 IVREF RADKE DRP 4)NIH R21 - ROLE OF MIR-181A-5P IN ADENOVIRUS 14P1 INDUCED ACUTE LUNG INJURY 5)NIH RO3 - DEVELOPMENT OF ANTIBODIES TO SPECIFIC CELL SURFACE MARKERS TO ASSESS MACROPHAGE POLARIZATION DURING ADENOVIRUS 14 AND 14P1 INFECTION IN THE SYRIAN HAMSTER. 6)NIH R24 - MODERNIZATION OF SMALL ANIMAL CAGING FOR INFECTIOUS DISEASE STUDIES AT THE BOISE VAMC 7)BIOMERIEUX, INC. - UTILIZATION AND IMPACT OF URINE CULTURE & SUSCEPTIBILITY RESULTS ON THE CLINICAL OUTCOMES OF URINARY TRACT INFECTIONS IN OUTPATIENT PRIMACY CARE AND TELEHEALTH SETTINGS 8)PARATEK PHARMACEUTICALS - INVESTIGATING THE ANTI-INFLAMMATORY ACTIVITIES OF OMADACYCLINE 9)ALTO PHARMACEUTICALS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER. 10)PCORI - FUNCTIONAL IMPROVEMENT IN OSA AND COPD WITH A TELEHEALTH LIFESTYLE AND EXERCISE INTERVENTION (FOCUSED) 11)JANSSEN RESEARCH & DEVELOPMENT, LLC - MULTICOHORT STUDY TO CUSTOMIZE IBRUTINIB TREATMENT REGIMENS FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. 893258 true true false false false false false false false false true false false false false true true false false false false false false false false false false false false false false false false false false false false false false false false false false true false false false true 2 0 18 true false false false false false false false false false false false false false false X 7 7 false false false false false true true true true false false true true true false false false true false false ID X MICAH ROOS 2084221000 500 W FORT STREET BLDG 117 BOISE ID 83702 MARGARET K ALDAPE EXECUTIVE DI 40.00 X 82136 0 22500 MICAH ROOS CHIEF FINANC 40.00 X 75113 0 2500 MARTIN BLAIR DIRECTOR 10.00 X 0 0 0 MARGARET DOUCETTE PRESIDENT 10.00 X X 0 0 0 AMBER FISHER DIRECTOR 10.00 X 0 0 0 JANET HINES TREASURER 10.00 X X 0 0 0 ANDREW WILPER VICE PRESIDE 10.00 X X 0 0 0 DAVID WOOD CHAIRMAN 10.00 X X 0 0 0 ROBERT WOOD SECRETARY 10.00 X 0 0 0 157249 25000 false false false 303897 177002 480899 CLINICAL TRIAL REVENUES 541700 380826 380826 IPA REIMBURSEMENT REVENUES 541700 207949 207949 ADMINISTRATIVE REVENUES 541700 25365 25365 PHARMACY FEES 541700 3780 3780 617920 17281 17281 REFUND OF REGISTRATION COSTS 1640 1640 CREDIT CARD REWARDS 468 468 2108 1118208 637309 X 169596 169596 445835 438148 7687 23920 23676 244 50406 36509 13897 1800 480 1320 12500 12500 169163 147650 21513 975 707 268 240 240 9152 9152 2510 368 2142 34743 34743 3179 3179 RESEARCH SUPPLIES 185866 185866 DUES AND SUBSCRIPTIONS 21904 15217 6687 SUBJECT PATIENT EXPENSE 742 742 1132531 893258 239273 0 119649 121964 303978 204690 135890 203273 25672 16341 713274 598496 68656 114778 653845 661046 31174 51986 31174 51986 X 554783 560316 67888 48744 622671 609060 653845 661046 -14323 712 X false true X true false X 1921156 1730851 1406022 708008 480899 6246936 1251307 292215 354200 351189 354200 2603111 3172463 2023066 1760222 1059197 835099 8850047 8850047 46690 4934 4391 101 2108 58224 8908271 652408 0.99350 0.99500 X PART II, LINE 10 OTHER INCOME 58,224 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 713274 598496 114778 114778 X 1473120 712 354200 354912 1118208 1118208 1486731 354200 354200 1132531 1132531 SCHEDULE D, PAGE 3, PART X THE ORGANIZATION QUALIFIES AS A TAX-EXEMPT ORGANIZATION UNDER SECTION 501 (C)(3) OF THE INTERNAL REVENUE CODE. THE ORGANIZATION PERIODICALLY ASSESSES WHETHER IT HAS INCURRED INCOME TAX EXPENSE OR RELATED INTEREST OR PENALTIES IN ACCORDANCE WITH ACCOUNTING FOR UNCERTAIN TAX POSITIONS. NO SUCH AMOUNTS WERE RECOGNIZED FOR THE YEARS ENDING SEPTEMBER 30, 2024 AND 2023, RESPECTIVELY. THE ORGANIZATION FOLLOWS THE INCOME TAX STANDARD FOR UNCERTAIN TAX POSITIONS. THE ORGANIZATION HAS EVALUATED THEIR TAX POSITIONS AND DETERMINED THEY HAVE NO UNCERTAIN TAX POSITIONS AS OF SEPTEMBER 30, 2024 AND 2023. SHOULD THE ORGANIZATIONS TAX-EXEMPT STATUS BE CHALLENGED IN THE FUTURE, THE ORGANIZATIONS 2022, 2023, AND 2024 TAX YEARS ARE OPEN FOR EXAMINATION BY THE IRS. FORM 990, PAGE 2, PART III, LINE 4A EXPENDITURES RELATED TO RESEARCH AND EDUCATION. RESEARCH EXPENSES ASSOCIATED WITH THE FOLLOWING MAJOR GRANT PROJECTS: 1)NIH (U OF IDAHO SUB-AWARD) - IDAHO INBRE PROGRAM IVREF DOUCETTE 2)NIH (U OF IDAHO SUB-AWARD) - DHHS NIH INBRE4 IVREF HOBDEY DRP 3)NIH (U OF IDAHO SUB-AWARD) - DHHS NIH INBRE4 IVREF RADKE DRP 4)NIH R21 - ROLE OF MIR-181A-5P IN ADENOVIRUS 14P1 INDUCED ACUTE LUNG INJURY 5)NIH RO3 - DEVELOPMENT OF ANTIBODIES TO SPECIFIC CELL SURFACE MARKERS TO ASSESS MACROPHAGE POLARIZATION DURING ADENOVIRUS 14 AND 14P1 INFECTION IN THE SYRIAN HAMSTER. 6)NIH R24 - MODERNIZATION OF SMALL ANIMAL CAGING FOR INFECTIOUS DISEASE STUDIES AT THE BOISE VAMC 7)BIOMERIEUX, INC. - UTILIZATION AND IMPACT OF URINE CULTURE & SUSCEPTIBILITY RESULTS ON THE CLINICAL OUTCOMES OF URINARY TRACT INFECTIONS IN OUTPATIENT PRIMACY CARE AND TELEHEALTH SETTINGS 8)PARATEK PHARMACEUTICALS - INVESTIGATING THE ANTI-INFLAMMATORY ACTIVITIES OF OMADACYCLINE 9)ALTO PHARMACEUTICALS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER. 10)PCORI - FUNCTIONAL IMPROVEMENT IN OSA AND COPD WITH A TELEHEALTH LIFESTYLE AND EXERCISE INTERVENTION (FOCUSED) 11)JANSSEN RESEARCH & DEVELOPMENT, LLC - MULTICOHORT STUDY TO CUSTOMIZE IBRUTINIB TREATMENT REGIMENS FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. FORM 990, PAGE 6, PART VI, LINE 7A VA DIRECTORS ARE EX-OFFICIO PER THE ORGANIZATION'S BY-LAWS. OTHER DIRECTORS AND OFFICERS ARE ELECTED BY A MAJORITY VOTE OF THE BOARD OF DIRECTORS. FORM 990, PAGE 6, PART VI, LINE 7B ARTICLES AND BY-LAWS DICTATE THAT CERTAIN ACTIONS MAY BE TAKEN BY A MAJORITY VOTE OF THE VA DIRECTORS. FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF THE FORM 990 IS AVAILABLE TO ALL DIRECTORS PRIOR TO FILING OF THE RETURN. THE EXECUTIVE DIRECTOR AND CHIEF FINANCE OFFICER REVIEWS THE FORM 990 BEFORE SIGNING AND REPORTS ANY ITEMS OF CONCERN TO THE OTHER DIRECTORS. FORM 990, PAGE 6, PART VI, LINE 15A THE BOARD OF DIRECTORS ARE RESPONSIBLE FOR DETERMINING, REVIEWING, AND APPROVING THE EXECUTIVE DIRECTOR'S COMPENSATION. FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REASONABLE WRITTEN REQUEST FOR SUCH INFORMATION. FORM 990, PART IX, LINE 11G PAYROLL PROCESSING FEES 0 6,053 0 RESEARCH SUPPORT 147,650 15,460 0 TOTAL 147,650 21,513 0 BOISE VA MEDICAL CENTER 500 WEST FORT STREET BOISE ID 83702 820465077 V.A CENTER ID US GOV NA false false false false false false false false false false false false false false true false true false false false BOISE VA MEDICAL CENTER N 354200 FAIR VALUE BOISE VA MEDICAL CENTER P 26000 CASH